Sign inJoin waitlistJoin the waitlist

Stephanie Blank

Obstetrics & Gynecology / Gynecologic Oncology · Icahn School of Medicine at Mount Sinai

Credentials: · · ·

History

Gynecologic Oncology
2000–2003
Obstetrics and Gynecology
Icahn School of Medicine at Mount Sinai
1996–2000
Icahn School of Medicine at Mount Sinai
1990–1994

Research

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian,…
Journal of Clinical Oncology · 2012 · 1,048 citations
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer
JAMA · 2015 · 421 citations
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E…
Journal of Clinical Oncology · 2024 · 323 citations

Melissa Frey
27 papers · 10 as a resident
Bhavana Pothuri
18 papers
JC
John Curtin
18 papers
Jason Wright
17 papers
FM
Franco Muggia
15 papers
Laura Havrilesky
15 papers
Sharonne Holtzman
15 papers · 15 as a fellow
Evan Myers
14 papers · 14 as a resident
Eloise Chapman-Davis
12 papers
Leslie Boyd
11 papers · 1 as a fellow
KO
Kenneth Offit
10 papers
Kristen Zeligs
10 papers

Grants

Comparative Modeling of Uterine Cancer
National Cancer Institute · U01
PI · $1.3M · Tufts Medical Center
2026–2031
Comparative Modeling for the Prevention and Control of Uterine Cancer
National Cancer Institute · U01
PI · $4.2M · Tufts Medical Center
2021–2027

Clinical trials

A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL)
Principal investigator · Completed · Phase 2
Tigris Pharmaceuticals
2007–2008
Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
Principal investigator · Completed · Phase 2
NYU Langone Health
2007–2013
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2026–2028
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2031